PC
ENTL

Paulson & Co’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History

Paulson & Co’s Portfolio ENTL Stock Details ENTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-102,702
Closed -$1.7M – 105
2017
Q2 		$1.7M Buy
+102,702
New +$1.43M 0.02% 95

Other funds holding ENTL

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
DGI
Discovery Group I Chicago, Illinois $262M AUM 29.24% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co's ENTL Position: Q3 2017 in Review

Paulson & Co sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q3 2017, closing a stake of 102,702 shares — an estimated $1.7M sold.

Paulson & Co first reported a position in ENTL in Q2 2017 and held it in 1 quarter. The position peaked at $1.7M in Q2 2017. 72 funds tracked by Wall St. Rank hold ENTL as of Q3 2017.

  • Paulson & Co reported no remaining Entellus Medical, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Paulson & Co sold 102,702 Entellus Medical, Inc. Common Stock shares in Q3 2017, an estimated $1.7M.
  • Paulson & Co first reported a position in Entellus Medical, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Paulson & Co's Entellus Medical, Inc. Common Stock position peaked at $1.7M in Q2 2017.
  • 72 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.